Jonathan Pachter

Chief Scientific Officer Verastem. inc

Seminars

Thursday 18th September 2025
VS-7375: An Oral, Selective KRAS G12D (ON/OFF) Inhibitor with Potent Preclinical Anti- Tumor Efficacy & Promising Initial Clinical Data
1:30 pm
  • Characterization as a selective KRAS G12D (ON/OFF) inhibitor and differentiation vs. other RAS inhibitors
  • Exploring combinations in preclinical models to define clinical directions
  • Clinical update
Tuesday 16th September 2025
Panel Discussion: Identifying the Right Combination for Different Cancers by Tailoring RAS Inhibitors for Tumor-Specific Reponses
11:30 am
  • Overcoming the complexity of tumor biology and multiple signaling pathways to select the optimal combination approach for different cancer types
  • How can patient-specific genetic profiles and tumor microenvironment data inform the design of more effective combination therapies?
  • How do RAS inhibitors alter the tumor microenvironment and improve response to current standard of care cancer treatments?
Jonathan Pachter (1)